A novel medication approach to treating obstructive sleep apnoea.
作者信息
Burgess Keith
机构信息
Departmemt of Health Sciences, Macquarie University, Epping, NSW, Australia.
Northern Beaches Hospital, Frenchs Forest, NSW, Australia.
出版信息
J Physiol. 2025 May;603(10):2899-2900. doi: 10.1113/JP288922. Epub 2025 May 22.
Abstract
摘要
相似文献
1
A novel medication approach to treating obstructive sleep apnoea.一种治疗阻塞性睡眠呼吸暂停的新型药物治疗方法。
J Physiol. 2025 May;603(10):2899-2900. doi: 10.1113/JP288922. Epub 2025 May 22.
2
Examining the impact of multilevel upper airway surgery on the obstructive sleep apnoea endotypes and their utility in predicting surgical outcomes.探讨多水平上气道手术对阻塞性睡眠呼吸暂停表型的影响及其在预测手术结局中的应用。
Respirology. 2022 Oct;27(10):890-899. doi: 10.1111/resp.14280. Epub 2022 May 21.
3
Changes in pharyngeal collapsibility and genioglossus reflex responses to negative pressure during the respiratory cycle in obstructive sleep apnoea.阻塞性睡眠呼吸暂停患者呼吸周期中咽壁塌陷和颏舌肌反射反应对负压的变化。
J Physiol. 2020 Feb;598(3):567-580. doi: 10.1113/JP278433. Epub 2020 Jan 15.
4
Atomoxetine and fesoterodine combination improves obstructive sleep apnoea severity in patients with milder upper airway collapsibility.托莫西汀和非索罗定联合治疗可改善上气道塌陷较轻的患者阻塞性睡眠呼吸暂停严重程度。
Respirology. 2022 Nov;27(11):975-982. doi: 10.1111/resp.14326. Epub 2022 Jul 10.
5
Pharyngeal distensibility during expiration is an independent predictor of the severity of obstructive sleep apnoea.咽扩张度在呼气时是阻塞性睡眠呼吸暂停严重程度的独立预测指标。
Respirology. 2019 Jun;24(6):582-589. doi: 10.1111/resp.13474. Epub 2019 Jan 24.
6
The noradrenergic agent reboxetine plus the antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: a double-blind, placebo-controlled, randomised crossover trial.去甲肾上腺素能药物瑞波西汀联合抗毒蕈碱类药物氢溴酸东莨菪碱可降低睡眠呼吸暂停严重程度：一项双盲、安慰剂对照、随机交叉试验。
J Physiol. 2021 Sep;599(17):4183-4195. doi: 10.1113/JP281912. Epub 2021 Jul 14.
7
Breath-holding as a means to estimate the loop gain contribution to obstructive sleep apnoea.屏气作为估计阻塞性睡眠呼吸暂停中环路增益贡献的一种手段。
J Physiol. 2018 Sep;596(17):4043-4056. doi: 10.1113/JP276206. Epub 2018 Jul 6.
8
The effect of M-current activation on controller gain and obstructive sleep apnoea severity: a randomised controlled trial using flupirtine.M电流激活对控制器增益和阻塞性睡眠呼吸暂停严重程度的影响：一项使用氟吡汀的随机对照试验。
J Physiol. 2025 May;603(10):3245-3260. doi: 10.1113/JP288337. Epub 2025 Apr 3.
9
Upper-Airway Collapsibility and Loop Gain Predict the Response to Oral Appliance Therapy in Patients with Obstructive Sleep Apnea.上气道可塌陷性和环路增益可预测阻塞性睡眠呼吸暂停患者对口腔矫治器治疗的反应。
Am J Respir Crit Care Med. 2016 Dec 1;194(11):1413-1422. doi: 10.1164/rccm.201601-0099OC.
10
Non-continuous positive airway pressure treatment options in obstructive sleep apnoea: A pathophysiological perspective.阻塞性睡眠呼吸暂停的非持续气道正压治疗选择：病理生理学视角。
Sleep Med Rev. 2021 Dec;60:101521. doi: 10.1016/j.smrv.2021.101521. Epub 2021 Jul 1.
本文引用的文献
1
The effect of M-current activation on controller gain and obstructive sleep apnoea severity: a randomised controlled trial using flupirtine.M电流激活对控制器增益和阻塞性睡眠呼吸暂停严重程度的影响：一项使用氟吡汀的随机对照试验。
J Physiol. 2025 May;603(10):3245-3260. doi: 10.1113/JP288337. Epub 2025 Apr 3.
2
The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants.KCNQ 钾通道开放剂作为新型抗抑郁药的潜力。
CNS Drugs. 2022 Mar;36(3):207-216. doi: 10.1007/s40263-021-00885-y. Epub 2022 Mar 8.
3
Drug Therapy in Obstructive Sleep Apnea.阻塞性睡眠呼吸暂停的药物治疗
Sleep Med Clin. 2018 Jun;13(2):203-217. doi: 10.1016/j.jsmc.2018.03.004.
4
The role of high loop gain induced by intermittent hypoxia in the pathophysiology of obstructive sleep apnoea.间歇性低氧诱导的高环路增益在阻塞性睡眠呼吸暂停病理生理学中的作用。
Sleep Med Rev. 2015 Aug;22:3-14. doi: 10.1016/j.smrv.2014.10.003. Epub 2014 Oct 15.
5
New insights from the measurement of loop gain in obstructive sleep apnoea.阻塞性睡眠呼吸暂停环路增益测量的新见解。
J Physiol. 2012 Apr 15;590(8):1781-2. doi: 10.1113/jphysiol.2012.228643.
6
Pathogenesis of obstructive and central sleep apnea.阻塞性和中枢性睡眠呼吸暂停的发病机制。
Am J Respir Crit Care Med. 2005 Dec 1;172(11):1363-70. doi: 10.1164/rccm.200412-1631SO. Epub 2005 Aug 11.
Zotero 插件